Free Newsletter
Amgen in new talks over ESA safety
Amgen is sitting down with regulators for a little frank talk about the safety warnings on Aranesp and Epogen, its two cash cows in the anemia market that were worth $6.6 billion in revenue last year. The biotech giant also says that the Oncologic Drugs Advisory Committee plans to meet and review the ESA drugs in the first quarter of next year. Revenue from the ESA category has been falling steadily as federal and private payers enforce limits on their use. That trend has forced Amgen to restructure and pay more attention to pipeline development projects.
- here's the AFX report on Amgen
Related Articles:
Analyst: Anemia drug warnings 'not bad'
Amgen income hammered as anemia drug use drops
Amgen, J&J win a round in anemia controversy
Amgen discusses the future with analysts
New rules limit use of anemia drugs
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
SHARE
WITH: